StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study

Venous Thromboembolism Clinical Trial

— SAVER  

Official title:

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02679664
• Other study ID #: 20160047-01H
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 2016
• Est. completion date: July 2020

Study information

• Verified date: February 2020
• Source: Ottawa Hospital Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce post-thrombotic syndrome (PTS) in venous thromboembolism (VTE) patients.

Eligible consenting patients who developed acute, symptomatic, and objectively confirmed proximal leg deep vein thrombosis (DVT) and/or PE will be randomized and equally allocated to 2 trial arms, either the treatment group (rosuvastatin tablet (20 mg/day) or the control group (usual care). The pilot trial consists of up to 4 study contacts over 6 months: screening, randomization, telephone follow-up (90 days), and final study visit (180 days).

Description:

The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce post-thrombotic syndrome (PTS) in venous thromboembolism (VTE) patients.

• SCREENING: Research coordinators at each pilot site will screen patients for eligibility and will complete detailed logs of all patients meeting inclusion (both enrolled and excluded). After providing informed consent, eligibility will be confirmed by the following tests : a lipid profile, A1C test/ CBC, transaminase (ALT) levels, Creatinine and pregnancy test (if a female of child bearing potential). Consenting participants who (following screening) do not meet eligibility criteria will be followed up to establish feasibility outcomes.

• RANDOMIZATION: Randomization will be conducted using an Interactive Web based Randomization System in a 1:1 ratio for treatment (20mg rosuvastatin od) or control (no study drug).

• STUDY DRUG DISPENSING: Participants randomized to the treatment arm will be dispensed x 200 20mg tablets of rosuvastatin along with a medication diary.They will be educated on study drug dosing regimen (20mg tablet od), how to complete their medication diary and on the possible side-effects of rosuvastatin. They will be advised to contact either the study coordinator, investigator or go directly to the emergency department should they experience any symptoms in particular anything muscle related.

• BASELINE. Assessments include;

• Demographic data;

• Concomitant medications (antiplatelet, anti-inflammatories, anticoagulation);

• Type of index VTE;

• PTS Villalta leg assessment conducted by both the participant (Patient Reported Villalta [PRV] questionnaire) and a qualified blinded independent observer (The Villalta scale is the most extensively validated tool and is recommended by the ISTH) - (Primary Outcome);

• Risk factors for recurrent VTE, bleeding and arterial vascular events;

• Medical history including prior VTE, Arterial disease, Liver disease and Glucose Intolerance.

• 90 DAY FOLLOW UP [Treatment arm only]: Participants randomized to treatment will be followed up via telephone or email at 90 days (+/- 21 days);

• Participants will be asked questions to screen for;

• Study outcomes: Suspected VTE, Arterial, Bleeding and/ or Muscle Events Patients who report any unexplained muscle symptoms will be asked to have their Creatine kinase (CK) levels tested within 2 weeks of reporting the symptoms. Study drug will be discontinued if CK levels are markedly elevated (> 10 x ULN).;

• Study Drug compliance

• Adverse events.

• Concomitant medication will be reviewed in case of any contraindications. Changes or additions in concomitant anticoagulation therapy, anti-platelet or anti - inflammatory medication will also be recorded.

• Study coordinators will log all follow up contact attempts.

• FINAL STUDY VISIT (180 days (+/- 21 days): All study participants will be asked to attend an in person study visit at 180 days (+/-21) for;

• Follow-up of study outcomes; VTE, Arterial, Bleeding and Muscle events;

• Study drug compliance;

• Relevant (S)AE(s).

• Repeat PTS leg assessment (using the Villalta scale) both by a qualified independent observer and the participant (Primary outcome);

• Study drug compliance: Medication Diaries and used medication bottles will be collected by the study coordinator. Coordinator will perform a pill count and reconcile with the participants medication diary. Coordinator will also ask participant reasons for any missed doses.

ADJUDICATION OF STUDY OUTCOMES: All Bleeding, VTE and Arterial Suspected Events as well as deaths will be recorded on a suspected event CRF along with any diagnostic imaging/ tests and will trigger a more in-depth evaluation, and review by an independent adjudication committee.

ADVERSE EVENTS: AEs will be elicited, monitored and recorded throughout the study.

All events meeting the definition of an SAE (as per ICH-GCP) must be reported to the SAVER Trial Office in Ottawa, Canada within 24 h of awareness.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 312
• Est. completion date: July 2020
• Est. primary completion date: January 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and/or PE (segmental or greater) diagnosed in the last 30 days.

Exclusion Criteria:

1. Unable or unwilling to provide written informed consent

2. = 18 years of age

3. Currently prescribed a statin

4. A medical history or current diagnosis of any of the following:

• Abdominal aortic aneurysm,

• Peripheral arterial disease,

• Stroke,

• Transient ischemic attack (TIA),

• Myocardial infarction (MI),

• Acute coronary syndromes,

• Stable angina,

• Coronary or other arterial revascularization

5. LDL-C >4.91 mmol/L

6. LDL-C between 1.81mmol/L to 4.9mmol/L AND 10 ASCVD risk score >10%

7. Diabetes mellitus or pre-diabetes

8. Contraindication to rosuvastatin;

• Hypersensitivity or intolerance to statins;

• History of muscle disorders or statin-related muscle pain;

• Liver disease (active liver disease or unexplained elevations of serum transaminases exceeding 3 times the upper limit of normal);

• Chronic kidney disease (Creatinine clearance < 30ml/min)

• Currently pregnant or breast feeding;

• Taking cyclosporine.

9. Life expectancy less than 3 months, as judged by the investigator

10. Unstable medical or psychological condition that would interfere with trial participation.

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• Rosuvastatin
20 mg tablet of rosuvastatin

Locations

Country	Name	City	State
Canada	Nova Scotia Health Authority	Halifax	Nova Scotia
Canada	Hamilton Health Sciences Corporation	Hamilton	Ontario
Canada	Lawson Health Research Institute, London Health Sciences Centre	London	Ontario
Canada	Sir Mortimer B. Davis Jewish General Hospital	Montreal	Quebec
Canada	Ottawa Hospital	Ottawa	Ontario
Norway	Østfold Hospital Trust	Grålum

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Countries where clinical trial is conducted

Canada,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants recruited per center per month - [Study Feasibility]	Study feasibility as indicated by the number of participants recruited per center per month.	3 years
Primary	Incidence of PTS	Incidence of post thrombotic syndrome (PTS), as measured by the Villalta scale at 6 months by both an 'Blinded Independent Assessor' and self reported by the participant.	180 days (+/- 21 days)
Secondary	Symptomatic recurrent major VTE	Symptomatic recurrent major VTE (proximal DVT or segmental or larger PE) in patients taking generic rosuvastatin (full trial primary outcome). Coordinators will submit a report to the independent adjudication committee for participants that undergo investigation for suspected recurrent VTE during the study.	180 days (+/- 21 days)
Secondary	Components of major VTE	Proximal DVT; Segmental or greater PE	180 days (+/- 21 days)
Secondary	Non-major VTE	Distal DVT(distal to the trifurcation of the popliteal vein); Isolated sub-segmental PE; Superficial phlebitis > 5 cm; Superficial phlebitis = 5 cm	180 days (+/- 21 days)
Secondary	Arterial Vascular Events	At the 3-month call and 6-month visit the research coordinator will follow an interview script to screen for inter-current suspected arterial events. Any reported potential arterial events will trigger a more in-depth evaluation.; Fatal myocardial infarction; Non-fatal myocardial infarction; Hospitalization for unstable angina; Coronary artery revascularization; Sudden cardiac death; Ischemic stroke	180 days (+/- 21 days)
Secondary	All-cause mortality	All-cause mortality	180 days (+/- 21 days)
Secondary	Bleeding	At each follow-up visit the research coordinator will follow an interview script to screen for suspected major and clinically relevant non-major bleeding events. Suspected bleeding that lasts more than 10 minutes, required intervention to control or for which the patient sought medical attention will be adjudicated by an independent committee using ISTH bleeding criteria.	180 days (+/- 21 days)
Secondary	Muscle Toxicity	Participants reporting symptoms of muscle toxicity will have their CK levels tested for safety. Study drug will be discontinued if CK levels are markedly elevated (>10 x ULN)	180 days (+/- 21 days)